vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Aligos Therapeutics, Inc. (ALGS). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $169.0K, roughly 823.4× Aligos Therapeutics, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -11763.9%, a 11799.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -72.1%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -50.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
ADMA vs ALGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $169.0K |
| Net Profit | $49.4M | $-19.9M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -12907.7% |
| Net Margin | 35.5% | -11763.9% |
| Revenue YoY | 18.4% | -72.1% |
| Net Profit YoY | -55.9% | 75.8% |
| EPS (diluted) | $0.20 | $4.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $169.0K | ||
| Q3 25 | $134.2M | $741.0K | ||
| Q2 25 | $122.0M | $965.0K | ||
| Q1 25 | $114.8M | $311.0K | ||
| Q4 24 | $117.5M | $606.0K | ||
| Q3 24 | $119.8M | $1.3M | ||
| Q2 24 | $107.2M | $1.1M | ||
| Q1 24 | $81.9M | $694.0K |
| Q4 25 | $49.4M | $-19.9M | ||
| Q3 25 | $36.4M | $-31.5M | ||
| Q2 25 | $34.2M | $-15.9M | ||
| Q1 25 | $26.9M | $43.1M | ||
| Q4 24 | $111.9M | $-82.2M | ||
| Q3 24 | $35.9M | $-19.3M | ||
| Q2 24 | $32.1M | $5.1M | ||
| Q1 24 | $17.8M | $-34.9M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -12907.7% | ||
| Q3 25 | 38.0% | -3827.4% | ||
| Q2 25 | 35.1% | -1924.0% | ||
| Q1 25 | 30.4% | -6187.5% | ||
| Q4 24 | 32.6% | -3393.2% | ||
| Q3 24 | 33.1% | -1610.5% | ||
| Q2 24 | 36.6% | -2489.5% | ||
| Q1 24 | 26.7% | -3176.7% |
| Q4 25 | 35.5% | -11763.9% | ||
| Q3 25 | 27.1% | -4256.0% | ||
| Q2 25 | 28.1% | -1643.8% | ||
| Q1 25 | 23.4% | 13854.7% | ||
| Q4 24 | 95.2% | -13556.1% | ||
| Q3 24 | 30.0% | -1540.7% | ||
| Q2 24 | 29.9% | 477.0% | ||
| Q1 24 | 21.7% | -5023.5% |
| Q4 25 | $0.20 | $4.23 | ||
| Q3 25 | $0.15 | $-3.04 | ||
| Q2 25 | $0.14 | $-1.53 | ||
| Q1 25 | $0.11 | $-2.11 | ||
| Q4 24 | $0.45 | $-13.10 | ||
| Q3 24 | $0.15 | $-3.07 | ||
| Q2 24 | $0.13 | $0.81 | ||
| Q1 24 | $0.08 | $-5.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $77.8M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $53.5M |
| Total Assets | $624.2M | $88.5M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $77.8M | ||
| Q3 25 | $61.4M | $99.1M | ||
| Q2 25 | $90.3M | $122.9M | ||
| Q1 25 | $71.6M | $137.9M | ||
| Q4 24 | $103.1M | $56.9M | ||
| Q3 24 | $86.7M | $74.9M | ||
| Q2 24 | $88.2M | $94.5M | ||
| Q1 24 | $45.3M | $112.7M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $53.5M | ||
| Q3 25 | $431.2M | $71.8M | ||
| Q2 25 | $398.3M | $101.9M | ||
| Q1 25 | $373.4M | $116.4M | ||
| Q4 24 | $349.0M | $-29.0M | ||
| Q3 24 | $231.9M | $50.1M | ||
| Q2 24 | $188.3M | $67.2M | ||
| Q1 24 | $153.7M | $59.8M |
| Q4 25 | $624.2M | $88.5M | ||
| Q3 25 | $568.7M | $109.8M | ||
| Q2 25 | $558.4M | $134.7M | ||
| Q1 25 | $510.6M | $150.7M | ||
| Q4 24 | $488.7M | $70.1M | ||
| Q3 24 | $390.6M | $88.4M | ||
| Q2 24 | $376.4M | $108.8M | ||
| Q1 24 | $350.9M | $127.9M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-21.7M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-21.7M | ||
| Q3 25 | $13.3M | $-24.3M | ||
| Q2 25 | $21.1M | $-15.5M | ||
| Q1 25 | $-19.7M | $-20.9M | ||
| Q4 24 | $50.2M | $-18.4M | ||
| Q3 24 | $25.0M | $-20.1M | ||
| Q2 24 | $45.6M | $-19.5M | ||
| Q1 24 | $-2.2M | $-22.7M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -0.49× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -3.85× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
